Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: GlobeNewswire
IRVINE, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus”), a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced the presentation of data from the European and Canadian Phase III EVB-003 head-to-head comparative trial demonstrating that its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator met its primary endpoint of non-inferiority at Day 30 in subjects with moderate to severe glabellar lines, also known as "frown lines," compared to onabotulinumtoxinA (Botox®). The results were presented today in a poster titled “A Multicenter Phase III Study Comparing prabotulinumtoxinA and onabotulinumtoxinA for the Treatment of Glabellar Lines” by Dr. Patricia Ogilvie, M.D., dermatologist and Principal Investigator of the study, at the 2018 Aesthetic & Anti-Aging Medicine World Congress (AMWC), being held April 4-7 in Monte-Carlo, Monaco. The results presen
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus to Report First Quarter Financial Results on May 7, 2024Business Wire
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau® [Yahoo! Finance]Yahoo! Finance
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®Business Wire
- Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN]CNN
- Counterfeit Botox has been found in several states. Here's what consumers should know. [CNN]CNN
EOLS
Earnings
- 3/7/24 - Miss
EOLS
Sec Filings
- 4/3/24 - Form 8-K
- 3/29/24 - Form 4
- 3/21/24 - Form 4
- EOLS's page on the SEC website